Diabetics with early kidney disease lack protective "anti-aging" hormones Klotho

A new study by King's College London showed that diabetics with early kidney disease lack protective "anti-aging" hormones Klotho. Klotho protein is a new type of anti-aging-related proteins that play an important role in resisting body aging. Klotho is secreted by the kidneys. Studies using recombinant dog proteins have shown that secreted Klotho protein can inhibit the aging of the body, play the role of anti-oxidation, anti-apoptotic and protect the cardiovascular, kidney and other systems so as to regulate a variety of aging-related diseases.

A study published on Feb. 13 in the European Diabetes Research Association journal Diabetologia shows that Klotho may play an important role in the development of common kidney disease in diabetic patients. This means that Klotho's expression level may serve as a potential marker for predicting the risk of kidney disease, as well as developing new targets for the treatment and prevention of kidney disease in patients with type 1 diabetes. The preliminary work of the research team also shows that Klotho protects the vascular system from changes associated with abnormal aging, such as arterial wall thickening (atherosclerosis), which characterizes age-related diseases such as diabetes, heart disease and hypertension.

In this study, scientists studied blood and urine samples from 78 patients with type 1 diabetes, 33 of which showed signs of early stage of diabetic nephropathy (known as microalbuminuria). The researchers found that Klotho levels in the blood of patients with microalbuminuria were lower in patients with microalbuminuria than those without microalbuminuria. Klotho levels in patients without microalbuminuria were the same as those for healthy adults.

"This is the first time that Klotho has been associated with type 1 diabetic nephropathy," said Dr. Giuseppe Maltese of the first author of the study at the King's College London. "This finding means that new disease markers and potential treatments can be developed."

"With further research, through the larger type 1 and type 2 diabetes patients, we hope to expand the scope of this study in order to identify early high-risk patients in the progress of kidney disease and cardiovascular disease," said Dr. Janaka Karalliedde, senior author.

Researchers say the study will help scientists better understand how this hormone contributes to healthy aging and how Klotho's flaws lead to age-related illnesses. As part of the ARK (King Academy Aging Research) research program, they are further researching Klotho's role in aging and longevity.

The limitations of this study include its relatively small sample size and selectivity, making it impossible for researchers to determine the causal relationship between Klotho and kidney disease progression. By the way, Flarebio provides you with recombinant proteins of good quality such as recombinant Ptpra.

Scientists have summarized the newly-discovered molecular mechanism after antibiotic therapy

Scientists around the world are struggling to find a solution to the problem of bacterial multidrug resistance. A new study conducted by the University of Copenhagen using recombinant human proteins shows that even sensitive bacteria produce so-called "drug-resistant strains cells". A comprehensive analysis of this phenomenon helps to better select drug treatments and even stimulate new antibiotic to treat resistant infections of refractory strains.

In a recent issue of the journal Science, Alexander Harms and colleagues from the University of Copenhagen summarized the newly-discovered molecular mechanisms of chronic and recurrent infections caused by surviving bacteria after antibiotic therapy.

"The surprising resilience of bacteria is usually due to dormancy-like physiological state called persistence," says Harms. "At this point, bacteria are resistant to a variety of antibiotics and exogenous drugs. Bacterial cells can convert to bacterial persistence by activating specialized procedures. Once converting to bacterial persistence, the bacteria may be resistant to antibiotic therapy and can even be revived, resulting in recurrence of infection after cessation of antibiotic therapy."

Bacterial persistence, to some extent, is triggered by bacterial toxins that shut down important cellular processes (such as protein synthesis or energy production), forcing bacterial cells into dormant conditions so that they are no longer readily killed by antibiotics. Bacterial persistence is like hibernating animals or spores produced by mushrooms and plants.

These procedures of bacteria are controlled by a regulatory compound known as the "magic spot" and play a central role in bacterial persistence. These important findings will provide a basis for the development of new diagnostic tools and a more effective treatment strategy for a range of bacterial infections. Flarebio provides you with high-quality recombinant proteins like recombinant Ptpra for your research.

To treat and prevent Alzheimer's disease by use of flash light?

Flash light can achieve removal of amyloid protein and reduce protein plaque generation and prevent and treat senile dementia, according research using recombinant human proteins. β-amyloid accumulation in the brain to form plaques is one of the hallmark of characteristics of the formation of Alzheimer's disease, and many currently-developed drugs take reducing brain β-amyloid levels as the goal. The field of drug development has been repeatedly hit, but the scientists did not give up β-amyloid plaques on the contribution of Alzheimer's disease. There are also scientists trying to take a more peculiar way to reduce brain β-amyloid accumulation. This week, the journal Nature published a study titled "Gamma frequencyentrainment attenuates amyloid load and modifies microglia". The researchers believed that brain electrical signal transients may lead to β-amyloid accumulation. Restoration of neural circuits to produce specific electrical shocks can reduce β-amyloid formation and activate immune cells to clear β-amyloid in the brain.

When the brain neuron network is activated synchronously, the oscillatory discharge is generated. This EEG frequency is 30-90 Hz, also known as γ-oscillation, which is thought to contribute significantly to high-level cognitive and perceptual responses. Authors such as Massachusetts Institute of Technology, Cai Lihui et al used the Alzheimer's mouse model to record neuronal activity. The results showed that after the decline in γ-amyloid protein accumulation of plaque formation, animal cognitive declined. They used optical genetics directly to stimulate neurons in the hippocampus of Alzheimer's model mice to produce γ-oscillations that significantly reduced β-amyloid formation in the brain region and activated microglia. Microglia is the brain immune cells, and it can remove β-amyloid protein after being activated.

The authors designed a noninvasive method of stimulating neurons in the brain. The mice were placed in a box filled with LED lamps and irradiated at a frequency of 40 Hz to visualize the primary visual cortex of the mice. The study found that this stimulus can reduce amyloid protein levels in the visual cortex of early Alzheimer's mice by 50% and reduce the number of amyloid plaques in the visual cortex of later-stage Alzheimer's mice.

The results showed that the frequency of 40 Hz can activate the microglia in the brain and improve the ability of amyloid removal, which can reduce the amyloid plaque formation, preventing and treating senile dementia. Treatment of Alzheimer's disease with γ-oscillations is a new therapeutic strategy, but whether it plays a role on humans needs to be further studied. By the way, Flarebio offers good-quality recombinant proteins like recombinant Ptpra at good prices.

Scientists find the link between DNA and chronic joint pain

Scientists at King's College London have discovered a link between DNA modification and chronic generalized joint pain, one of the main symptoms of fibromyalgia, and the study is funded by the Arthritis Research Foundation. Fibromyalgia is a common chronic condition that causes muscle and bone fatigue and widespread pain. Although fibromyalgia is very popular, the etiology is little understood, and the treatments are limited. What's worse, fibromyalgia can't be detected using routine tests such as scanning or X-ray detection. The disease affects 4% of the world. The study, published in the journal PLOS ONE which also has other studies on recombinant dog proteins, will help scientists develop a diagnosis of fibromyalgia through blood tests.

"Fibromyalgia is affected by genetic factors, but there are a number of complex intermediate processes between genes and diseases," said Frances Williams, Ph.D., one of the authors of the article from the Department of Twin and Genetic Epidemiology. "Identifying measurable epigenetic associations is an important step. What's more, these results will provide information on future studies of fibromyalgia and other chronic pain syndromes, such as irritable bowel syndrome."

Stephen Simpson, director of the British Arthritis Institute, commented on the study, "Millions of people in the UK suffer from fibromyalgia, and this exciting study has helped us understand how individuals' epigenetic differences affect fiber Myalgia and chronic extensive musculoskeletal pain. For people with long-standing fibromyalgia, they have been struggling to diagnose their pain symptoms. This study will help to better understand, manage and treatment joint pain."

The researchers used twins to study whether DNA methylation affects the way genes start up when they produce a particular protein and to observe whether there are differences between musculoskeletal pain patients and non-patients. Scientists have determined that patients with chronic extensive pain and non-patients have different levels of DNA methylation in the three genes. Preliminary indications suggest that people may have different methylation patterns in their DNA and that this may affect the initiation of some genes and may lead to a variety of conditions. Flarebio offers superior recombinant proteins including recombinant Ptpra at good prices.